Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CDNA
BuyPremium GrowerFLAGCareDx, Inc. · Healthcare · United States · $2.6B · Avg Vol: $63M/d
CareDx has quality Q66 and strong momentum M84, but value at V28 is below the calibrated floor, so stage one fails. Insider selling of 0.49% is separately adverse.
COMPANY DESCRIPTION
CareDx, Inc. is a leading precision medicine company focused on developing and commercializing diagnostic solutions for transplant patients, including proprietary molecular diagnostic tests and digital health software for monitoring organ health and rejection. The company's competitive moat is built upon its innovative, clinically validated tests like AlloSure and AlloMap, strong intellectual property, and deep integration with transplant centers globally. CareDx holds a leading position in a critical and specialized healthcare niche with high barriers to entry.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 321.8M | 280.3M | 333.8M | 379.8M | 5.7% | 458.1M | 495.1M | 524.0M | 17.5% |
| EPS | -0.59 | -1.44 | -3.54 | 1.00 | -0.40 | — | 2.08 | 1.20 | 1.33 | 9.9% |
| Shares | — | 53.5M | 51.5M | 54.8M | 50.9M | -4.9% | 51.7M | — | — | — |
| Debt | — | 39.0M | 34.2M | 28.4M | 26.2M | -12.4% | 19.2M | — | — | — |
| Equity | — | 430.9M | 261.3M | 378.4M | 303.1M | -11.1% | — | — | — | — |
| Op CF | — | -25.2M | -18.4M | 38.0M | 42.0M | 10.5% | 93.7M | — | — | — |
| Inv CF | — | -228.5M | 40.4M | -0.5M | 2.2M | — | — | — | — | — |
| Fin CF | — | -4.5M | -29.6M | -5.6M | -93.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CDNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CDNA | CareDx, Inc.(you) | $2.6B | 75 | Buy |
| VCYT | Veracyte, Inc. | $3.5B | 80 | Strong Buy |
| SHC | Sotera Health Company | $5.5B | 81 | Strong Buy |
| BLLN | BillionToOne, Inc. | $4.4B | 61 | Hold |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| WGS | GeneDx Holdings Corp. | $2.6B | 24 | Sell |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.1%